PTU - Polskie Towarzystwo Urologiczne
list of articles:

Prostate cancer screening - results of the studies
Article published in Urologia Polska 2004/57/4.


Jakub Dobruch 1, Andrzej Borówka 1, Artur A. Antoniewicz 1, Piotr Chłosta 2
1 Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Centralnego Szpitala Kolejowego w Warszawie
Kierownik kliniki i ordynator oddziału: prof. dr hab. Andrzej Borówka
2 Dział Urologii ¦więtokrzyskiego Centrum Onkologii w Kielcach
Kierownik działu: dr med. Stefan Olszewski


prostate, prostate cancer, screening, PSA, mortality


Screening for prostate cancer (PCa) allows to distinguish men with organ confined prostate cancer in whom radical treatment leading to complete cancer removal may be performed. However, before mass screening is carried out its efficiency in reduction of disease specific mortality must be proven.
The purposes of the present study were evaluation of diagnostic efficacy of prostate cancer screening, identification of diagnostic methods most valuable for screening and demonstration whether prostate screening is reasonable.
The results of the studies presented in MEDLINE regarding the prostate cancer screening involving large number of men and evaluating the diagnostic efficacy of various tests were analyzed.
Prostate biopsy was performed in most of the studies in case of: increased plasma PSA and abnormal digital rectal examination (DRE). Icreased PSA and/or suggestive of prostate cancer DRE was observed respectively in 3,1-19,5% and 3-10% of screened men. Prostate cancer was diagnosed in majority of cases in men in whom biopsy was preformed because of increased PSA. Finaly PCa was present in 24-33% of men subjected to prostate biopsy. However clinical and pathological characteristics of PCa detected by screening were more favourable than characteristics of PCa detected in not screened population of men.
Cyclic PSA measurements are most valuable screening test for prostate cancer. It is performed only in men at the age suitable for radical treatment. Prostate cancer screening leads to increase in men dignosed with PCa. It also leads to increase in percentage of organ confined and well differentiated prostate cancer. Therefore it is possible to distinguish men in whom prostate cancer may be radically treated. However the data indicating that prostate cancer screening decreases disease specific mortality is still lacking.


  1. Mettlin CJ, Murphy GP, Babaian RJ et al: Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1997; 80: 1814-1817.
  2. Smith DS, Humphrey PA, Catalona WJ: The early detection of prostate carcinoma with prostate-specific antigen. Cancer 1997; 80: 1852-1856.
  3. De Antoni EP: Eight years of 'Prostate Cancer Awareness Week'. Lessons in screening and early detection. Cancer 1997; 80: 1845-1851.
  4. Labrie F, Candas B, Dupont A et al: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
  5. Cusan N et al: Diagnosis of advanced noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212-217.
  6. Reissigl A, Horninger W, Fink K et al: Prostate carcinoma screening in the County of Tyrol, Austria. Cancer 1997; 80: 1818-1829.
  7. Standaert B, Denis L: The European Randomized Study of Screening for Prostate Cancer. Cancer 1997; 80: 1830-1834.
  8. Schroder FH, Denis LJ, Roobol M: The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92: 1-13.
  9. Rietbergen JB, H¶demaeker RF, B¶ken, Kruger AE: The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 1192-1198.
  10. Catalona WJ, Richie JP, Ahmann FR et al: Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicentre clinical trial of 6630 men. J Urol 1994; 151: 1283-1290.
  11. Schröder FH, van der Maas P, Beemsterb¶r P et al: Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-1823.
  12. Flanigan RC, Catalona WJ, Richie JP et al: Accuracy of digital recital examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994; 152: 1506-1509.
  13. Carter HB, Hamper UM, Sheth S et al: Evaluation of transrectal ultrasound in the diagnosis of prostate cancer. J Urol 1989; 142: 1008-1010.
  14. Kirby RS, Christmas TJ, Brawer MK: Clinical diagnosis: Kirby RS, Christmas TJ, Brawer MK (red); Prostate cancer, Mosby, London 2001, str. 49-57.
  15. Labrie F, Dupont A, Suburu R et al: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-852.
  16. Hugosson J, Aus G, Lilja H et al: Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003; 169: 1720-1723.
  17. H¶demaker RF, van der Kwast TH, B¶r R et al: Pathologic features of prostate cancer found at population-based screening with a fouryear interval. JNCI 2001; 93: 1153-1158.
  18. Tornblom M, Eriksson H, Franzen S et al: Lead time associated with screening for prostate cancer. Int J CKancer 2004; 108: 122- 129.
  19. Humphrey PA, Keetch DW, Smith DS et al: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-820.
  20. Stamey TA, Donaldson AN, Yemoto CE et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. Journal of Urology 1998; 160: 2412-247.
  21. Stamey TA, Freiha FS, McNeal JE et al: Localised prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-938.
  22. Krumholtz JS, Carvalhal GF, Ramos CG et al: Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469- 474.
  23. Ohori M, Wheeler TM, Dunn JK et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714-1720.
  24. Humphrey PA, Keetch DW, Smith DS et al: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-820.
  25. B¶r R, Schröder FH: Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 1999; 40: 130-134.
  26. Bartsch G, Horninger W, Klocker H et al: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
  27. Schröder FH, Wildhagen MF: Badania przesiewowe w wykrywaniu raka stercza. Obecny stan wiedzy i perspektywy na przyszło¶ć. EBU EUUS 200; 6; 9-16; BJU international 2001; 88; 811-817, wersja polska. CDC Website. http//wonder. cdc. gov/2001.
  28. Potosky AL, Feuer EJ, Levin DL: Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiologic Reviews 2001; 23: 181-186.
  29. Chu KC, Tajone RE, Freeman HP: Trends in prostate cancer mortality among black and white men in the United States. Cancer 2003; 97: 1507-1516.
  30. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-67.
  31. Slevin TJ, Donelly N, Clarkson J et al: Prostate cancer testing: behaviour, motivation and attitudes among western Australian men. Med J Aust 1999; 171: 185-188.
  32. Slevin TJ, Donelly N, Clarkson JP et al: Prostate cancer testing: behaviour, motivation and attitudes among western Australian men. Med J Aust 1999; 171: 185-188.
  33. Lu-Yao G, Albertsen PC, Stanford JL et al: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740.


Jakub Dobruch
Oddział Urologii Centralnego Szpitala Kolejowego
ul. Bursztynowa 2
04-749 Warszawa
tel. 0 503 072 230